Clinical Trials Search | Clareo Health

Showing 1-5 of 5 trials

ET-01 in Subjects With Lateral Canthal Lines, LCL-210

NCT04985916

This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).

Lateral Canthal Lines, LCLCrow's Feet

Eirion Therapeutics Inc.280 participantsStarted Jul 2021

Scottsdale, Arizona, United States • San Diego, California, United States • Aventura, Florida, United States +16 more locations

COMPLETEDPHASE2

Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines

NCT03911102

A Phase 2a, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Treatment of Moderate or Severe Lateral Canthal Lines (LCL).

Lateral Canthal Lines

Revance Therapeutics, Inc.63 participantsStarted Mar 2019

Sacramento, California, United States • Sarasota, Florida, United States • Itasca, Illinois, United States +1 more locations

COMPLETEDPHASE3

Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines

NCT04225260

This is a phase 3, multicenter, open-label study to evaluate the safety of QM1114-DP for the long term treatment of moderate to severe Glabellar (Frown) Lines (GL) and Lateral Canthal Lines (Crow's Feet and LCL).

Glabellar LinesLateral Canthal Lines

Galderma R&D902 participantsStarted Jan 2020

Birmingham, Alabama, United States • Scottsdale, Arizona, United States • Fremont, California, United States +27 more locations

COMPLETEDPHASE2

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

NCT00884234

The purpose of this study is to determine the safety and efficacy of 2 sequential doses of RT001 compared to vehicle control following applications at Baseline (Day 0) and Week 2.

Lateral Canthal Lines

Revance Therapeutics, Inc.30 participantsStarted Feb 2009

Houston, Texas, United States

COMPLETEDPHASE2

Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

NCT01124565

This study's objective is to evaluate if RT001 is safe and well-tolerated following two (2) sequential applications.

Lateral Canthal LinesCrow's FeetFacial Wrinkles

Revance Therapeutics, Inc.40 participantsStarted May 2010

Birmingham, Alabama, United States • San Diego, California, United States • Omaha, Nebraska, United States

Data from ClinicalTrials.govTerms

Filters

Filters

ET-01 in Subjects With Lateral Canthal Lines, LCL-210

Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines

Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

ET-01 in Subjects With Lateral Canthal Lines, LCL-210

Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines

Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults